Anglo-Swedish pharma major AstraZeneca has entered into a collaboration, exclusive option and license agreement with privately-held UK biopharma Quell Therapeutics. 9 June 2023
German radiopharmaceutical biotech ITM Isotope Technologies has announced an equity investment round of 255 million euros ($273 million) led by Temasek. 9 June 2023
Privately-held US firms Aviko Radiopharmaceuticals and Neutron Therapeutics have announced the formation of a strategic partnership to advance boron neutron capture therapy (BNCT) to treat cancer. 8 June 2023
Californian biopharma FibroGen suffered a setback in part of its development of pamrevlumab, sending its shares 11% lower in Wednesday’s trading. 8 June 2023
Legend Biotech and Janssen have announced the submission of a supplemental Biologics License Application (sBLA) to the US Food and Drug Administration (FDA) relating to their partnered asset Carvykti (ciltacabtagene autoleucel). 8 June 2023
Privately-held Dutch biotech Amarna Therapeutics has appointed Dr Henk Streefkerk as the company’s new chief executive and medical director. 7 June 2023
Flagship Pioneering founded company Ring Therapeutics today announced the appointment of Konstantin Konstantinov as its chief technology officer. 7 June 2023
USA-based Paratek Pharmaceuticals saw its shares leap almost 14% to $2.22 by mid-morning today, after it revealed it has entered into a definitive agreement to be acquired by Gurnet Point Capital and Novo Holdings. 6 June 2023
Shares of US firm Ultragenyx Pharmaceutical and UK-based Mereo BioPharma rose in pre-market activity, up 6.5% to $54.48 and 11.4% at $1.17, respectively, after the companies released new showing that setrusumab rapidly induced bone production in osteogenesis imperfecta (OI)-affected patients. 6 June 2023
Along with the big pharma players showing off the potential of their cancer drugs at the 2023 Annual Meeting of the American Society of Clinical Oncology (ASCO), biotech companies have been making their presence felt, too. 5 June 2023
Data presented at the American Society of Clinical Oncology (ASCO) reinforce enthusiasm for a new approach being developed by companies including Elevation Oncology. 5 June 2023
More than three dozen state-level enforcers reached a $102.5 million deal with Indivior to resolve claims that the drugmaker monopolized the market for the opioid addiction treatment Suboxone (buprenorphine) ahead of a looming September trial. 5 June 2023
Building on the extraordinary success of its platform in producing an effective coronavirus vaccine, German mRNA specialist BioNTech is making inroads on a project which broadens its focus to include checkpoint inhibition. 2 June 2023
US biosimilars developer Coherus BioSciences saw its share rise 5% to $4.05 pre-market, after it announced it will launch Yusimry (adalimumab-aqvh) next month. 2 June 2023
Phase II results from Austrian arenaviral technology firm Hookipa Pharma show a 43% objective response rate (ORR) for its lead candidate in head and neck cancer. 2 June 2023
California, USA-based biotech start-up Eikon Therapeutics has acquired exclusive rights to multiple early- to mid-stage assets, leveraging its proprietary Single Molecule Tracking (SMT) technology to drive strategic decisions around its new drug pipeline. 2 June 2023
Swiss contract development and manufacturing organization (CDMO) Lonza today announced it has acquired Dutch biotech company Synaffix, which is focused on commercializing its clinical-stage technology platform for the development of antibody-drug conjugate (ADCs). 1 June 2023
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024